|
81
|
298
|
3fz1A |
Crystal structure of a benzthiophene inhibitor bound to human cyclin-dependent kinase-2 (cdk-2) |
|
62
|
291
|
3g33A |
Crystal structure of cdk4/cyclin d3 |
|
84
|
298
|
3f5xA |
Cdk-2-cyclin complex with indazole inhibitor 9 bound at its active site |
|
77
|
298
|
3ezrA |
Cdk-2 with indazole inhibitor 17 bound at its active site |
|
74
|
298
|
3eocA |
Cdk2/cyclina complexed with a imidazo triazin-2-amine |
|
75
|
298
|
3ezvA |
Cdk-2 with indazole inhibitor 9 bound at its active site |
|
84
|
297
|
3eidA |
Cdk2/cyclina complexed with a pyrazolopyridazine inhibitor |
|
80
|
298
|
3ej1A |
Cdk2/cyclina complexed with a pyrazolopyridazine inhibitor |
|
83
|
299
|
3dogA |
Structure of thr 160 phosphorylated cdk2/cyclin a in complex with the inhibitor n-&-n1 |
|
85
|
299
|
3ddqA |
Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor roscovitine |
|
85
|
298
|
3ddpA |
Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor cr8 |
|
81
|
319
|
3blqA |
Crystal structure of human cdk9/cyclint1 in complex with atp |
|
86
|
320
|
3blrA |
Crystal structure of human cdk9/cyclint1 in complex with flavopiridol |
|
78
|
318
|
3blhA |
Crystal structure of human cdk9/cyclint1 |
|
82
|
300
|
3bhuA |
Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor meriolin 5 |
|
82
|
300
|
3bhvA |
Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor variolin b |
|
85
|
300
|
3bhtA |
Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor meriolin 3 |
|
75
|
298
|
2xnbA |
Discovery and characterisation of 2-anilino-4-(thiazol-5-yl) pyrimidine transcriptional cdk inhibitors as anticancer agents |
|
74
|
298
|
2xmyA |
Discovery and characterisation of 2-anilino-4-(thiazol-5-yl) pyrimidine transcriptional cdk inhibitors as anticancer agents |
|
80
|
296
|
2x1nA |
Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design |
|
84
|
302
|
2wxvA |
Structure of cdk2-cyclin a with a pyrazolo(4,3-h) quinazoline-3- carboxamide inhibitor |
|
85
|
302
|
2wpaA |
Optimisation of 6,6-dimethyl pyrrolo 3,4-c pyrazoles: identification of pha-793887, a potent cdk inhibitor suitable for intravenous dosing |
|
75
|
296
|
2whbA |
Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design |
|
87
|
302
|
2wipA |
Structure of cdk2-cyclin a complexed with 8-anilino-1-methyl-4,5-dihydro- 1h-pyrazolo[4,3-h] quinazoline-3-carboxylic acid |
|
91
|
297
|
2wmbA |
Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin a |
|
86
|
302
|
2wihA |
Structure of cdk2-cyclin a with pha-848125 |
|
76
|
297
|
2wmaA |
Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin a |
|
80
|
295
|
2wfyA |
Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design |
|
52
|
288
|
2w9fB |
Crystal structure of cdk4 in complex with a d-type cyclin |
|
86
|
296
|
2wevA |
Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design |
|
77
|
298
|
2w1hA |
Fragment-based discovery of the pyrazol-4-yl urea (at9283), a multi- targeted kinase inhibitor with potent aurora kinase activity |
|
57
|
289
|
2w96B |
Crystal structure of cdk4 in complex with a d-type cyclin |
|
61
|
291
|
2w9zB |
Crystal structure of cdk4 in complex with a d-type cyclin |
|
53
|
291
|
2w99B |
Crystal structure of cdk4 in complex with a d-type cyclin |
|
80
|
298
|
2vtqA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
77
|
298
|
2vtjA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design |
|
82
|
298
|
2vtmA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
79
|
298
|
2vthA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design |
|
81
|
298
|
2vtpA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
78
|
298
|
2vtaA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
74
|
298
|
2w17A |
Cdk2 in complex with the imidazole pyrimidine amide, compound (s)-8b |
|
78
|
298
|
2vtiA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
84
|
298
|
2vtlA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design |
|
75
|
298
|
2vtsA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
79
|
298
|
2vtnA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
78
|
298
|
2vtoA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
76
|
298
|
2w05A |
Structure of cdk2 in complex with an imidazolyl pyrimidine, compound 5b |
|
79
|
298
|
2vu3A |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
|
82
|
298
|
2vtrA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design |
|
75
|
298
|
2vttA |
Identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design. |
